From GlobeNewswire:

ublished in the Journal of the American Medical Association, Shanghai Junshi Biosciences announced positive results from the NEOTORCH phase 3 trial. The study evaluated the efficacy and safety of toripalimab in combination with perioperative platinum-based chemotherapy for patients with resectable stage III non-Small Cell Lung Cancer. Results showed a significant improvement in event-free survival for patients receiving toripalimab, marking a transformative change in the diagnosis and treatment landscape of lung cancer in China and beyond. The study enrolled the largest sample of resectable stage III NSCLC patients in China and demonstrated a manageable safety profile.



Read more: Junshi Biosciences Announces JAMA Publication of Results